SCHEMBL22476355

SCHEMBL22476355

CCCCOC(=O)N1CC=C(OS(=O)(=O)C(F)(F)F)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.35
STS P08842 7/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
HRH2 P25021 2/20 0.35
HRH1 P35367 2/20 0.35
MMP13 P45452 2/20 0.35
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
DRD4 P21917 1/20 0.34
DRD5 P21918 1/20 0.34
DRD3 P35462 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29698862 0.88 LMNA (0.39) LMNAPOLBSMN1; SMN2PTGDR2STS
SCHEMBL2036756 0.85 GRM5 (0.31) ADORA1
SCHEMBL212404 0.83 RORC (0.37) PTGDR2CHRM2CHRM1HRH1MMP13
SCHEMBL23123262 0.82 PKM (0.36)
SCHEMBL15598574 0.81 PDK4 (0.36) DRD2DRD1DRD4DRD5DRD3
SCHEMBL25412676 0.80 LMNA (0.34) LMNAPOLBSMN1; SMN2PTGDR2STS
SCHEMBL212403 0.80 PDK4 (0.46) STSADORA1
SCHEMBL749417 0.80 GRM5 (0.49) SMN1; SMN2PTGDR2
SCHEMBL2458379 0.79 QDPR (0.38) SMN1; SMN2DRD2DRD1DRD4DRD5
SCHEMBL308840 0.79 BACE1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY 2023-06-15 US disclosed
US-10793575-B2 Oxoisoquinoline derivatives CARNA BIOSCIENCES, INC. (JP) 2020-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10793575-B2 Oxoisoquinoline derivatives BCL6, BCL6B, BCL3 LMNA 1585/4885POLB 586/4885SMN1; SMN2 1223/4885
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 CHRM5, CHRM1, CHRM2 LMNA 4600/4885POLB 3228/4885SMN1; SMN2 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.